Posterior fossa ependymomas in children and adolescents - the state of the art
Authors:
- Marcos Devanir Silva Da CostaMCMarcos Devanir Silva Da Costa
- Carolina Torres SoaresCSCarolina Torres Soares
- Patricia Alessandra DastoliPDPatricia Alessandra Dastoli
- Jardel Mendonça NicácioJNJardel Mendonça Nicácio
- Frederico Adolfo Benevides SilvaFSFrederico Adolfo Benevides Silva
- Maria Teresa de Seixas AlvesMAMaria Teresa de Seixas Alves
- Michael Jenwei ChenMCMichael Jenwei Chen
- Andrea Maria CappellanoACAndrea Maria Cappellano
- Nasjla Saba SilvaNSNasjla Saba Silva
- Sergio CavalheiroSCSergio Cavalheiro
Open Access
- 13 September 2023
- journal article
- abstracts
- Published by Archives of Pediatric Neurosurgery in Archives of Pediatric Neurosurgery
- Vol. 5 (3) , e20102023
Abstract
Central nervous system tumors in pediatric patients represent the most frequent solid tumor type in this age group, especially ependymomas, which comprise 5% of childhood intracranial tumors, and occur mainly in the posterior fossa. The MEDLINE and ClinicalTrials databases were searched for studies on posterior fossa ependymomas, 64 studies met the search criteria. Symptoms include ataxia, vertigo, headache, vomiting, cranial nerve palsies, or papilledema, resulting from intracranial hypertension due to obstruction of CSF circulation. Imaging examination often reveals posterior fossa ependymomas in the fourth ventricle or cerebellopontine angle; they may extend through the foramina of Luschka, Magendie, and/or magnum. These tumors cause a significant mass effect, displacing rather than invading the hidbrain, and may involve vessels or cranial nerves, making surgical resection difficult. Various radiological features have been studied to distinguish between ependymomas and other histological types, as well as between ependymoma subtypes. The 2021 WHO classification of central nervous system tumors classifies ependymomas by location. Three types occur in the posterior fossa: subependymomas, PF-A, and PF-B. These are differentiated by the degree of DNA methylation and CpG islands, which can be assessed by immunohistochemical analysis with H3K27me3. The consensus on the treatment of posterior fossa ependymomas in children advocates the maximum possible surgical resection, followed by radiotherapy in patients >1 year. Chemotherapy remains controversial, with no survival gain. Recent studies suggest molecular subgroups as an independent prognostic factor in posterior fossa ependymomas. The therapeutic challenge of ependymomas requires new treatment options, based on new technologies and molecular discoveries.Keywords
This publication has 45 references indexed in Scilit:
- Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experienceChild's Nervous System, 2020
- Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a costCancer, 2019
- Impact of radiation therapy and extent of resection for ependymoma in young children: A population‐based studyPediatric Blood & Cancer, 2017
- Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomeActa Neuropathologica, 2017
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variantsActa Neuropathologica, 2016
- Posterior fossa tumors in children: developmental anatomy and diagnostic imagingChild's Nervous System, 2015
- Posterior fossa ependymoma: current insightsChild's Nervous System, 2015
- Neuroimaging of pediatric posterior fossa tumors including review of the literatureJournal of Magnetic Resonance Imaging, 2011
- Ependymal tumors in childhoodPediatric Blood & Cancer, 2005
- Adjuvant chemotherapy of childhood posterior fossa ependymoma: Cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: A Childrens Cancer Group studyMedical and Pediatric Oncology, 1996